.

Make Better Decisions

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Accenture
Cantor Fitzgerald
Moodys
Daiichi Sankyo
UBS
Farmers Insurance
McKinsey
Mallinckrodt
Deloitte
Express Scripts

Generated: December 18, 2017

DrugPatentWatch Database Preview

OMNARIS Drug Profile

« Back to Dashboard

When do Omnaris patents expire, and when can generic versions of Omnaris launch?

Omnaris is a drug marketed by Astrazeneca Pharms and is included in one NDA. There are six patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and eighty-three patent family members in fifty-one countries.

The generic ingredient in OMNARIS is ciclesonide. There are seven drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the ciclesonide profile page.

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Astrazeneca PharmsOMNARISciclesonideSPRAY, METERED;NASAL022004-001Oct 20, 2006RXYesYes► Subscribe► SubscribeY► Subscribe
Astrazeneca PharmsOMNARISciclesonideSPRAY, METERED;NASAL022004-001Oct 20, 2006RXYesYes► Subscribe► SubscribeY► Subscribe
Astrazeneca PharmsOMNARISciclesonideSPRAY, METERED;NASAL022004-001Oct 20, 2006RXYesYes► Subscribe► SubscribeY► Subscribe
Astrazeneca PharmsOMNARISciclesonideSPRAY, METERED;NASAL022004-001Oct 20, 2006RXYesYes► Subscribe► SubscribeY► Subscribe
Astrazeneca PharmsOMNARISciclesonideSPRAY, METERED;NASAL022004-001Oct 20, 2006RXYesYes► Subscribe► SubscribeYY► Subscribe
Astrazeneca PharmsOMNARISciclesonideSPRAY, METERED;NASAL022004-001Oct 20, 2006RXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for OMNARIS

Drugname Dosage Strength RLD Submissiondate
ciclesonideNasal Spray250 mcgOmnaris2/13/2012

International Patent Family for Tradename: OMNARIS

Country Document Number Estimated Expiration
Peru07122001► Subscribe
Iceland2453► Subscribe
Bulgaria65799► Subscribe
Australia649472► Subscribe
Bulgaria104020► Subscribe
World Intellectual Property Organization (WIPO)9953899► Subscribe
Spain2234681► Subscribe
European Patent Office1670482► Subscribe
China101869570► Subscribe
Georgia, Republic ofP20022669► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Colorcon
Boehringer Ingelheim
Teva
Daiichi Sankyo
Dow
US Department of Justice
UBS
Accenture
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot